<?xml version="1.0" encoding="UTF-8"?>
<p id="para3760">Viral hepatitis A and E are major causes of morbidity and mortality related to acute hepatitis in countries of the Asia-Pacific that have medium and high HDIs and whose populations have low access to clean drinking water and sanitation facilities (see 
 <xref rid="box1" ref-type="boxed-text">panel 1</xref> for a list of priority areas for liver diseases related to viral hepatitis). Of all deaths due to acute hepatitis in the region, 89% occur in medium-HDI countries, 9% in high-HDI countries, and 2% in countries with very high HDIs (
 <xref rid="fig6" ref-type="fig">figure 6</xref> ). 95% of deaths related to acute HAV and HEV in the region occur in medium-HDI countries (
 <xref rid="fig7" ref-type="fig">figure 7</xref> ). The SDGs, as part of the UN's 2030 Agenda for Sustainable Development, have ambitious goals in this regard. Goal 6 is to ensure availability and sustainable management of water and sanitation for all by 2030. Goal 6.1 calls to achieve universal and equitable access to safe and affordable drinking water for all, and Goal 6.2 aspires to achieve access to adequate and equitable sanitation and hygiene for all, as well as the end of open defecation.
 <xref rid="bib404" ref-type="bibr">
  <sup>404</sup>
 </xref> In the past decade, much progress has been made to increase access to drinking water and sanitation but still too many people lack access to a safe, sustainable water supply and sanitation services.
 <boxed-text id="box1">
  <label>Panel 1</label>
  <caption>
   <title>Priority areas of action for liver diseases related to viral hepatitis in the Asia-Pacific region</title>
  </caption>
  <p id="para10">
   <bold>Policy, planning, advocacy, and resource mobilisation (building infrastructure for sound policy and programme development)</bold>
  </p>
  <p id="para20">
   <italic>National priority actions</italic>
  </p>
  <p id="para30">
   <list list-type="simple" id="celist10">
    <list-item id="celistitem10">
     <label>•</label>
     <p id="para40">Create an adequate statutory and regulatory environment for prevention and control of viral hepatitis</p>
    </list-item>
    <list-item id="celistitem20">
     <label>•</label>
     <p id="para50">All heavily burdened countries to have fully funded control and elimination plans to achieve elimination by 2030</p>
    </list-item>
    <list-item id="celistitem30">
     <label>•</label>
     <p id="para60">Advocate and mobilise resources for prevention and control of viral hepatitis</p>
    </list-item>
    <list-item id="celistitem40">
     <label>•</label>
     <p id="para70">Create a fiscal space for new programmes with costed investment programmes and adopt domestic innovative finance tools where appropriate</p>
    </list-item>
   </list>
  </p>
  <p id="para80">
   <italic>International priority actions</italic>
  </p>
  <p id="para90">
   <list list-type="simple" id="celist20">
    <list-item id="celistitem50">
     <label>•</label>
     <p id="para100">Recognise the need to focus on countries with high viral hepatitis burdens and support national policy development</p>
    </list-item>
    <list-item id="celistitem60">
     <label>•</label>
     <p id="para110">Support national policy makers in their activity (ie, WHO, Unitaid, non-governmental organisations) and provide international support for financing measures (ie, Unitaid, the Global Fund, corporate donors)</p>
    </list-item>
   </list>
  </p>
  <p id="para120">
   <bold>Viral hepatitis surveillance</bold>
  </p>
  <p id="para130">
   <italic>National priority actions</italic>
  </p>
  <p id="para140">
   <list list-type="simple" id="celist30">
    <list-item id="celistitem70">
     <label>•</label>
     <p id="para150">Establish an effective surveillance system for viral hepatitis and improved capacity for complete and accurate disease reporting</p>
    </list-item>
    <list-item id="celistitem80">
     <label>•</label>
     <p id="para160">Standardise data collection systems for core and targeted surveillance of viral hepatitis</p>
    </list-item>
    <list-item id="celistitem90">
     <label>•</label>
     <p id="para170">Improve the epidemiological investigation and response capacity to outbreaks</p>
    </list-item>
    <list-item id="celistitem100">
     <label>•</label>
     <p id="para180">Identify or develop and evaluate evidence-based interventions for prevention and control of viral hepatitis</p>
    </list-item>
   </list>
  </p>
  <p id="para190">
   <italic>International priority actions</italic>
  </p>
  <p id="para200">
   <list list-type="simple" id="celist40">
    <list-item id="celistitem110">
     <label>•</label>
     <p id="para210">Support national policy makers</p>
    </list-item>
   </list>
  </p>
  <p id="para220">
   <bold>Viral hepatitis prevention</bold>
  </p>
  <p id="para230">
   <italic>National priority actions</italic>
  </p>
  <p id="para240">
   <list list-type="simple" id="celist50">
    <list-item id="celistitem120">
     <label>•</label>
     <p id="para250">Ensure all WHO elimination targets are addressed in plans</p>
    </list-item>
    <list-item id="celistitem130">
     <label>•</label>
     <p id="para260">Emphasise the importance of sanitary conditions and personal hygiene</p>
    </list-item>
    <list-item id="celistitem140">
     <label>•</label>
     <p id="para270">Ensure provision of harm reduction services, engage with marginalised groups (eg, prisoners, especially those who inject drugs), and ensure clear public health messages to encourage testing and treatment for HBV and HCV</p>
    </list-item>
    <list-item id="celistitem150">
     <label>•</label>
     <p id="para280">Determine the need to include hepatitis A vaccination in routine childhood immunisation through periodic seroepidemiological surveys, disease surveillance, and modelling and cost-effectiveness analyses and formulate a hepatitis A vaccination policy for patients with chronic liver disease</p>
    </list-item>
    <list-item id="celistitem160">
     <label>•</label>
     <p id="para290">Introduce hepatitis E vaccination in countries with high incidence of HEV infection</p>
    </list-item>
    <list-item id="celistitem170">
     <label>•</label>
     <p id="para300">Address operational challenges in the delivery of birth-dose HBV vaccination</p>
    </list-item>
    <list-item id="celistitem180">
     <label>•</label>
     <p id="para310">Promote the use of effective risk reduction interventions and strategies for HBV and HCV prevention</p>
    </list-item>
   </list>
  </p>
  <p id="para320">
   <italic>International priority actions</italic>
  </p>
  <p id="para330">
   <list list-type="simple" id="celist60">
    <list-item id="celistitem190">
     <label>•</label>
     <p id="para340">Support countries to decriminalise use of injected drugs and ensure equitable access to services for all (ie, non-governmental organisations, WHO, civil societies)</p>
    </list-item>
    <list-item id="celistitem200">
     <label>•</label>
     <p id="para350">Ensure appropriate funding for HBV vaccination, including birth doses (ie, Gavi, WHO) and support research and development into HCV vaccine development (ie, research funders and pharmaceutical companies)</p>
    </list-item>
   </list>
  </p>
  <p id="para360">
   <bold>Viral hepatitis care and treatment</bold>
  </p>
  <p id="para370">
   <italic>National priority actions</italic>
  </p>
  <p id="para380">
   <list list-type="simple" id="celist70">
    <list-item id="celistitem210">
     <label>•</label>
     <p id="para390">Develop standard procedures for management and guidelines on counselling, support, and care for patients with acute viral hepatitis</p>
    </list-item>
    <list-item id="celistitem220">
     <label>•</label>
     <p id="para400">Assure timely access to chronic HBV and HCV diagnosis, care, treatment, and supportive services and their integration into primary care settings</p>
    </list-item>
    <list-item id="celistitem230">
     <label>•</label>
     <p id="para410">Establish programmes to support care and treatment for marginalised individuals and populations</p>
    </list-item>
    <list-item id="celistitem240">
     <label>•</label>
     <p id="para420">Focus on substantially scaling up testing for HBV and HCV</p>
    </list-item>
    <list-item id="celistitem250">
     <label>•</label>
     <p id="para430">Create and evaluate simplified care pathways relevant to local settings and integrate them with existing services</p>
    </list-item>
    <list-item id="celistitem260">
     <label>•</label>
     <p id="para440">Ensure that testing for HBV and HCV is integrated into the broad health-care system, rather than in centralised facilities</p>
    </list-item>
    <list-item id="celistitem270">
     <label>•</label>
     <p id="para450">Promote task sharing and decentralisation of care through capacity building, training, and removal of requirements for specialised prescribing</p>
    </list-item>
    <list-item id="celistitem280">
     <label>•</label>
     <p id="para460">Develop and regularly update guidelines for the clinical management, counselling, and care of patients with viral hepatitis</p>
    </list-item>
   </list>
  </p>
  <p id="para470">
   <italic>International priority actions</italic>
  </p>
  <p id="para480">
   <list list-type="simple" id="celist80">
    <list-item id="celistitem290">
     <label>•</label>
     <p id="para490">Support operational research into simplified pathways for screening, diagnosis, and treatment of viral hepatitis, integrated and improved service delivery, and linkage to social welfare programmes</p>
    </list-item>
    <list-item id="celistitem300">
     <label>•</label>
     <p id="para500">Ensure access to quality diagnostics through an essential diagnostic list and prequalification of diagnostic tests for quality, performance, and safety (ie, WHO, funders)</p>
    </list-item>
    <list-item id="celistitem310">
     <label>•</label>
     <p id="para510">Support scientific models of care and research and development into novel diagnostics, suitable for decentralised settings (ie, research funders, Foundation for Innovative New Diagnostics, industry)</p>
    </list-item>
   </list>
  </p>
  <p id="para520">
   <bold>Access to treatment</bold>
  </p>
  <p id="para530">
   <italic>National priority actions</italic>
  </p>
  <p id="para540">
   <list list-type="simple" id="celist90">
    <list-item id="celistitem320">
     <label>•</label>
     <p id="para550">Ensure that all essential medicines for viral hepatitis are included in national programmes, with an emphasis on pangenotypic regimens</p>
    </list-item>
    <list-item id="celistitem330">
     <label>•</label>
     <p id="para560">Apply comprehensive policy approaches to promoting access, including compulsory licensing</p>
    </list-item>
   </list>
  </p>
  <p id="para570">
   <italic>International priority actions</italic>
  </p>
  <p id="para580">
   <list list-type="simple" id="celist100">
    <list-item id="celistitem340">
     <label>•</label>
     <p id="para590">Ensure that all essential medicines are prequalified and either available through voluntary licensing or the Medicines Patent Pool (ie, WHO, non-governmental organisations, civil society, funders)</p>
    </list-item>
    <list-item id="celistitem350">
     <label>•</label>
     <p id="para600">Support shared procurement mechanisms for treatment (ie, Pan American Health Organization)</p>
    </list-item>
   </list>
  </p>
  <p id="para610">
   <bold>Knowledge and awareness about viral hepatitis prevention, vaccination, risk factors, treatment, and management</bold>
  </p>
  <p id="para620">
   <italic>National priority actions</italic>
  </p>
  <p id="para630">
   <list list-type="simple" id="celist110">
    <list-item id="celistitem360">
     <label>•</label>
     <p id="para640">Increase the knowledge about viral hepatitis in the general population and promote a healthy lifestyle in patients who are newly diagnosed or living with chronic viral hepatitis</p>
    </list-item>
    <list-item id="celistitem370">
     <label>•</label>
     <p id="para650">Improve and expand the knowledge about viral hepatitis among health workers and carers</p>
    </list-item>
   </list>
  </p>
  <p id="para660">
   <italic>International priority actions</italic>
  </p>
  <p id="para670">
   <list list-type="simple" id="celist120">
    <list-item id="celistitem380">
     <label>•</label>
     <p id="para680">Support nations in their activities (ie, WHO, industry)</p>
    </list-item>
   </list>
  </p>
  <p id="para690">
   <bold>Monitoring progress</bold>
  </p>
  <p id="para700">
   <italic>National priority actions</italic>
  </p>
  <p id="para710">
   <list list-type="simple" id="celist130">
    <list-item id="celistitem390">
     <label>•</label>
     <p id="para720">National plans need clearly defined, measurable objectives and new indices of national progress need to be developed</p>
    </list-item>
   </list>
  </p>
  <p id="para730">
   <italic>International priority actions</italic>
  </p>
  <p id="para740">
   <list list-type="simple" id="celist140">
    <list-item id="celistitem400">
     <label>•</label>
     <p id="para750">The progress of individual countries towards elimination goals needs to be closely monitored (ie, Polaris, WHO, creation a new elimination index)</p>
    </list-item>
   </list>
  </p>
  <p id="para760">
   <bold>Research on prevention and control of viral hepatitis</bold>
  </p>
  <p id="para770">
   <italic>National priority actions</italic>
  </p>
  <p id="para780">
   <list list-type="simple" id="celist150">
    <list-item id="celistitem410">
     <label>•</label>
     <p id="para790">Research to monitor the changing epidemiological and virological patterns of hepatitis</p>
    </list-item>
    <list-item id="celistitem420">
     <label>•</label>
     <p id="para800">Reduce the risk of transmission</p>
    </list-item>
    <list-item id="celistitem430">
     <label>•</label>
     <p id="para810">Assess the impact of interventions and assess and develop new tools for prevention, diagnosis, care, and treatment</p>
    </list-item>
   </list>
  </p>
  <p id="para820">
   <italic>International priority actions</italic>
  </p>
  <p id="para830">
   <list list-type="simple" id="celist160">
    <list-item id="celistitem440">
     <label>•</label>
     <p id="para840">Support nations in their activities (ie, WHO, industry)</p>
    </list-item>
   </list>
  </p>
 </boxed-text>
</p>
